- In May 2026, American Healthcare REIT, Inc. reported first-quarter 2026 results showing revenue of US$650.77 million and net income of US$23.71 million, alongside a sharp year-on-year reduction in real estate impairment charges to US$418,000 for the first quarter of 2025.
- On the same day, the company cut its 2026 net income guidance to US$97.80 million–US$109.08 million, with expected diluted EPS lowered to US$0.51–US$0.57, signaling more cautious profit expectations despite the recent earnings improvement.
- Next, we'll examine how this reduced 2026 earnings guidance reshapes American Healthcare REIT's previously optimistic long-term growth and margin improvement narrative.
Uncover the next big thing with 29 elite penny stocks that balance risk and reward.
American Healthcare REIT Investment Narrative Recap
To own American Healthcare REIT, you need to believe its senior housing, skilled nursing and outpatient assets can keep converting favorable demographics into steady cash flows, despite reimbursement and occupancy pressures. The latest cut to 2026 net income and EPS guidance points to more muted near term earnings progress, but does not appear to alter the core demand story. For now, the key short term catalyst remains execution in Trilogy and SHOP, while reimbursement and hospital system headwinds stay the biggest risks.
The most relevant development alongside the guidance cut is the sharp reduction in real estate impairment charges to US$418,000 for the first quarter of 2025, versus US$21,706,000 a year earlier. While this does not offset lower 2026 earnings expectations, it does suggest fewer write downs in the existing portfolio, which matters for investors focused on near term earnings quality and how durable the current dividend and acquisition driven growth plans may be.
Yet investors should be aware that reimbursement risk across Medicaid and Medicare Advantage could still...
Read the full narrative on American Healthcare REIT (it's free!)
American Healthcare REIT's narrative projects $3.0 billion revenue and $236.0 million earnings by 2029. This requires 8.1% yearly revenue growth and roughly a $135.7 million earnings increase from $100.3 million today.
Uncover how American Healthcare REIT's forecasts yield a $58.08 fair value, a 16% upside to its current price.
Exploring Other Perspectives
Three members of the Simply Wall St Community currently see American Healthcare REIT’s fair value between US$39.37 and about US$73.94, showing a wide range of expectations. Against that backdrop, the recent earnings guidance cut and softer profit outlook highlight how sensitive the story is to margins in Trilogy and SHOP, so it can be helpful to compare several of these independent views before forming your own.
Explore 3 other fair value estimates on American Healthcare REIT - why the stock might be worth 21% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your American Healthcare REIT research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free American Healthcare REIT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate American Healthcare REIT's overall financial health at a glance.
Curious About Other Options?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com